Strategies to optimize the brain availability of central nervous system drug candidates.
BACKGROUND
Access to the CNS is essential for most neurotherapeutics to elicit their effects. Leveraging design strategies incorporating physicochemical properties, in vitro and in vivo assays to predict and measure brain penetration, and brain delivery approaches may enable the drug discovery community to improve access of drug candidates into the CNS compartment.


METHODS
This article reviews aspects of the most recent molecular design, in vitro and in vivo strategies, and delivery technologies to optimize the unbound brain concentrations (C (b,u)) of CNS molecules. Through this, the article provides insight into recent ideas and concepts in CNS drug molecule design, methods for evaluating CNS drug exposures and alternative approaches to maximize drug access to neurocompartments.


CONCLUSIONS
The most pharmacologically relevant measure in assessing a compound's pharmacodynamic response in the CNS is its C (b,u). The utilization of emerging design strategies, together with in vitro and in vivo assays, may enable the design of molecules with optimal C (b,u):C (p,u) (C (p,u), unbound plasma concentration) and appropriate C (b,u,) to elicit a biological response from the neurotherapeutic target. Where drug properties intrinsically render a compound CNS impaired, using novel CNS delivery approaches may result in sufficient C (b,u) to furnish a biological response.
Pfizer Worldwide Research and Development, Neuroscience Worldwide Medicinal Chemistry, 558 Eastern Point Road, Groton 06320, USA  travis.t.wager@pfizer.com.
Travis T
TT
Wager
Anabella
A
Villalobos
Patrick R
PR
Verhoest
Xinjun
X
Hou
Christopher L
CL
Shaffer